GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Days Payable

XENE (Xenon Pharmaceuticals) Days Payable : 0.00 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Days Payable?

Xenon Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2024 was $5.25 Mil. Xenon Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Xenon Pharmaceuticals's Days Payable or its related term are showing as below:

During the past 13 years, Xenon Pharmaceuticals's highest Days Payable was 58.34. The lowest was 58.34. And the median was 58.34.

XENE's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 122.35
* Ranked among companies with meaningful Days Payable only.

Xenon Pharmaceuticals's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same


Xenon Pharmaceuticals Days Payable Historical Data

The historical data trend for Xenon Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Days Payable Chart

Xenon Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xenon Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xenon Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Xenon Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Days Payable falls into.



Xenon Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Xenon Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

Days Payable (A: Dec. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2023 ) + Accounts Payable (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (8.598 + 5.07) / 2 ) / 0*365
=6.834 / 0*365
=N/A

Xenon Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

Days Payable (Q: Dec. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2024 ) + Accounts Payable (Q: Dec. 2024 )) / count ) / Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=( (5.425 + 5.07) / 2 ) / 0*365 / 4
=5.2475 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenon Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Gary Patou director
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W